Overview

Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if palifermin will reduce the incidence of dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation chemotherapy for treatment of unresectable stage III Non-Small Cell Lung Cancer (NSCLC).

Phase:

Phase 2

Details

Lead Sponsor:

Swedish Orphan Biovitrum

Collaborator:

Amgen

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Mitogens
Paclitaxel